Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07049575 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa
A Phase 1 study of Hidradenitis Suppurativa, sponsored by Incyte Corporation.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 20
- Study locations
NCT07049575: Recruiting Phase 1 study of Hidradenitis Suppurativa, sponsored by Incyte Corporation.
NCT07049575 is a Phase 1 study of Hidradenitis Suppurativa that is actively recruiting participants, run by Incyte Corporation. The registered enrollment target is 24 participants, below the 598-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target (96% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07049575, a Phase 1 study of Hidradenitis Suppurativa, is actively recruiting participants, sponsored by Incyte Corporation.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the maximal use of ruxolitinib cream in adult and adolescent participants with hidradenitis suppurativa.
Primary Outcome
Defined as adverse events reported for the first time or worsening of a pre-existing event after the first application of study drug.
Conditions Studied
Interventions
- DRUG Ruxolitinib Cream
Study Locations (20)
California
- First Oc Dermatology - Fountain Valley
- Amicis Research Center Valencia - Northridge
- Children'S Hospital of Orange County - Orange
- Clinical Trials Research Institute - Thousand Oaks
Florida
- Advanced Pharma Cr, Llc - Miami
- International Clinical Research Tennessee Llc - Sanford
- Lenus Research Medical Group, Llc - Sweetwater
- Trueblue Clinical Research - Tampa
New York
- Dr Bobby Buka, Md Greenwich Village - New York
- Equity Medical, Llc - New York
Arizona
- Saguaro Dermatology - Phoenix
Colorado
- Clarity Dermatology - Castle Rock
Georgia
- Lane Dermatology and Dermatologic Surgery - Columbus
Indiana
- Options Research Group, Llc - West Lafayette
Kentucky
- Equity Medical, Llc - Bowling Green
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2025-11-03 |
| Est. Completion | 2026-12-09 |
| Phase | Phase 1 |
What NCT07049575 shows while recruiting
NCT07049575 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 598-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Hidradenitis Suppurativa appearing as the primary indexed condition, and to 1 intervention - of which Ruxolitinib Cream is the first listed.
NCT07049575 names 20 study sites across 13 states, led by California, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT07049575 about?
NCT07049575 is a clinical study titled "Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa". The purpose of this study is to evaluate the maximal use of ruxolitinib cream in adult and adolescent participants with hidradenitis suppurativa.
What is the current status of trial NCT07049575?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2025-11-03. Estimated completion is 2026-12-09.
What conditions does trial NCT07049575 study?
This clinical trial studies the following conditions: Hidradenitis Suppurativa.
What interventions are being tested in trial NCT07049575?
The interventions under investigation include: Ruxolitinib Cream (DRUG).
Who is sponsoring clinical trial NCT07049575?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07049575 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hidradenitis Suppurativa
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07049575's enrollment target sits among peer trials
24 38th of 52 higher than 13 of 52 other Hidradenitis Suppurativa trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hidradenitis Suppurativa trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)
RECRUITING · Phase 1
-
Study of Single Doses of SBT777101 in Subjects With Hidradenitis Suppurativa
ACTIVE NOT RECRUITING · Phase 1
-
Aviclear for Hidradenitis Suppurativa (HS)
RECRUITING · NA
-
Topical Ruxolitinib 1.5% for Hidradenitis Suppurativa Treatment
RECRUITING · Phase 2
-
An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)
RECRUITING · Phase 3
-
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI